Sort
261,768 grants matching “gene therapy”
Preclinical Development and Clinical Proof of Concept of a Synthetic Nanoparticle
$3,748,514Lloyd Patrick Johnston · Selecta Biosciences, Inc. · U01 · FY2015 · DA
Core Support for Cancer Center
$3,746,138Israel David Goldman · Albert Einstein College Of Medicine, Inc · P30 · FY2016 · CA
Transcriptional Functions of Nuclear Receptors in Cancer Cells
$3,745,233Trevor K Archer · National Institute Of Environmental Health Sciences · ZIA · FY2010 · ES
Dissecting CCL5 contribution to antigen specific T cell responses in head and neck cancers
$3,742,682Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2025 · DE
Studies of Populations Exposed to Therapeutic Medical Radiation and Other Agents
$3,738,937Lindsay Morton · Division Of Cancer Epidemiology And Genetics · ZIA · FY2019 · CA
INTEGRATED DEVELOPMENT OF NOVEL MOLECULAR MAKERS
$3,738,884Johns Hopkins University · U01 · FY2000 · CA
Cancer Center Support (Core) Grant
$3,738,697Tyler E Jacks · Massachusetts Institute Of Technology · P30 · FY2014 · CA
MPN Research Consortium
$3,737,982Ronald Hoffman · Icahn School Of Medicine At Mount Sinai · P01 · FY2021 · CA
Transforming Research and Clinical Knowledge in Traumatic Brain Injury
$3,735,917Geoffrey T Manley · University Of California, San Francisco · U01 · FY2013 · NS
Causal Transcriptional Consequences of Human Genetic Variation
$3,734,413George M Church · Harvard Medical School · P50 · FY2012 · HG
Epigenetic and Transcriptional Functions of Nuclear Receptors and Chromatin Remodeling Proteins in Stem and Cancer Cells
$3,730,413Trevor K Archer · National Institute Of Environmental Health Sciences · ZIA · FY2017 · ES
Human CD3epsilon co-potentiation to boost immunotherapy
$3,730,200Diana Gil Pages · University Of Missouri-Columbia · U01 · FY2019 · CA
Cure Sickle Cell
$3,729,772Mary Eapen · Medical College Of Wisconsin · OT3 · FY2023 · HL
Transcriptional Functions of Nuclear Receptors in Cancer Cells
$3,729,190Trevor K Archer · National Institute Of Environmental Health Sciences · ZIA · FY2009 · ES
A Seamless Phase 2A-B Randomized Double Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of PQ 912 in Patients with Early Alzheimer's Disease
$3,726,446Howard Feldman · University Of California, San Diego · R01 · FY2022 · AG
Targeting the Epigenome for Lung Cancer Therapy
$3,726,032David Schrump · Clinical Sciences · Z01 · FY2007 · CA
Targeting the oncoprotein that drives FLC
$3,725,015Sanford M Simon · Rockefeller University · U54 · FY2019 · CA
Genomic Stratification of Ovarian Cancer Patients
$3,723,748Michael Birrer · Massachusetts General Hospital · RC4 · FY2010 · CA
Genetic, Cellular and Molecular Mechanisms in Autoimmunity to Retina
$3,720,450Rachel R. Caspi · National Eye Institute · ZIA · FY2020 · EY
Influenza and Emerging Infectious Diseases
$3,718,933Richard Davey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Prostate Cancer Imaging
$3,716,679Peter L. Choyke · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Growth Control in Multiple Myeloma
$3,715,800Bart Barlogie · Univ Of Arkansas For Med Scis · P01 · FY2009 · CA
PET Radiopharmaceutical Sciences
$3,714,482Victor W Pike · National Institute Of Mental Health · ZIA · FY2018 · MH
Human Biochemical Genetics
$3,707,650William Gahl · National Human Genome Research Institute · ZIA · FY2010 · HG
DCTD Computer Support
$3,704,220David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2016 · CA